Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Crizotinib Reduces Tumor Size in… >

Crizotinib Reduces Tumor Size in Patients with ALK Positive Lung Cancer

Published: September 7, 2012.
Released by American Society for Radiation Oncology  

Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago.

ALK gene rearrangements are found in around 5 percent of lung cancer tumors and are more common in people with lung cancer who never smoked. Crizotinib is an oral drug that was found to inhibit the effects of the ALK gene and to stop or reverse tumor growth.

In this phase II trial, researchers followed 901 patients for safety and 261 patients for tumor response; all of the patients had at least one prior chemotherapy treatment for their lung cancer. The overall response rate to crizotinib treatment was 60 percent and the median progression free survival (PFS) was eight months, confirming prior findings that crizotinib shrinks ALK-positive lung cancers and demonstrates a high PFS rate.

"This trial demonstrates that we have a good opportunity to shrink cancers and improve symptoms for patients with this subtype of lung cancer," said Gregory Riely, MD, PhD, lead author of the study and a medical oncologist at Memorial Sloan-Kettering Cancer Center in New York who specializes in treating lung cancer. "This confirms the results of prior studies and further shows that crizotinib can reduce the effects of symptoms, thereby improving the quality of life for thousands of patients who are diagnosed with this late-stage lung cancer. This study confirms that crizotinib is the standard of care for patients with ALK positive lung cancer."






The above story is based on materials provided by American Society for Radiation Oncology.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


comments powered by Disqus


Related »

Cancer 
9/4/13 
Researchers Study Survival in African American Versus Caucasian Lung Cancer Patients
DENVER – According to the American Cancer Society, an estimated 160,340 lung cancer deaths occurred in the United States in 2012, accounting for 28 percent of all cancer deaths. …
Cancer 
9/13/11 
Researchers Discover Blood Proteins Associated with Early Development of Lung Cancer
SEATTLE – A research team led by Fred Hutchinson Cancer Research Center has discovered proteins in the blood that are associated with early lung cancer development in mice and …
Women 
9/4/12 
Study Finds Increase in Number of Non-smokers Being Diagnosed with Lung Cancer
Vienna, Austria: There has been an increase in the number of non-smokers being diagnosed with non-small cell lung cancer, according to new findings. The report, which will be …
Cancer 
9/13/11 
Lung Cancer Signatures in Blood Samples May Aid in Early Detection
Lung cancer is one of the most common and deadly types of cancer. Mouse models of lung cancer recapitulate many features of the human disease and have provided new …
Cancer 
1/27/12 
New Lung Cancer Test Predicts Survival
In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team led by scientists at the University of California, San Francisco (UCSF) …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile